NEOK Bio

NEOK Bio is a biotechnology company focused on developing novel antibody-drug conjugates (ADCs) aimed at improving outcomes for cancer patients. NEOK is rapidly advancing bispecific ADCs, a cutting-edge innovation that utilizes bispecific antibodies targeting two complementary antigens, with the potential to enhance safety while increasing the efficacy of ADCs across a broader range of tumors. Backed by ABL Bio, Inc., a recognized leader in the field of antibody engineering, NEOK plans to initiate clinical studies for its two lead bispecific ADC candidates in solid tumor indications by mid-2026.